ABBOTT-LEVETIRACETAM 500 MG — DIN 02414791
LEVETIRACETAM : 500 MG · ABBOTT LABORATORIES, LIMITED · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ABBOTT-LEVETIRACETAM?
ABBOTT-LEVETIRACETAM 500 MG contains LEVETIRACETAM : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02414791, held by ABBOTT LABORATORIES, LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Dec-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ABBOTT-LEVETIRACETAM used for?
Adjunctive therapy in the management of patients with epilepsy who are not satisfactorily controlled by conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Levetiracetam cost around the world?
Levetiracetam is listed on 19 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Brazil | preco fabrica (ex-factory ceiling) | 17 | 192 | BRL███.██ |
| Spain | PVP con IVA (public price) | 135 | 146 | EUR███.██ |
| United States | acquisition | 5 | 119 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 39 | 73 | EUR███.██ |
| Saudi Arabia | public | 47 | 70 | SAR███.██ |
| Australia | ex-manufacturer | 13 | 60 | AUD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 31 | 59 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 14 | 53 | CZK███.██ |
| United Arab Emirates | public | 39 | 47 | AED███.██ |
| Greece | producer price (ex-factory) | 30 | 30 | EUR███.██ |
| South Africa | single exit price | 27 | 27 | ZAR███.██ |
| Bahrain | retail (max) | 11 | 26 | BHD███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 26 | NOK███.██ |
| Slovakia | categorised final price | 21 | 22 | EUR███.██ |
| Hungary | producer price (ex-factory) | 18 | 20 | HUF███.██ |
| Romania | max producer price | 12 | 15 | RON███.██ |
| United Kingdom | hospital | 11 | 11 | GBP███.██ |
| Luxembourg | reimbursement | 6 | 6 | EUR███.██ |
| Morocco | PPV (public price) | 3 | 5 | MAD███.██ |
1007 pack listings across 484 brand entries and 17 price bases, refreshed 08 Sep 2026. Ranges span every Levetiracetam pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Levetiracetam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
33 holders have a Canadian DIN containing Levetiracetam, across 109 DINs, of which 47 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 8 | 4 | LEVETIRACETAM, PHARMA-LEVETIRACETAM, PMS-LEVETIRACETAM | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 4 | 4 | MINT-LEVETIRACETAM, MINT-LEVETIRACETAM SOLUTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 4 | SANDOZ LEVETIRACETAM | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 6 | 3 | JAMP LEVETIRACETAM TABLETS, JAMP-LEVETIRACETAM | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 3 | TEVA-LEVETIRACETAM, TVA-LEVETIRACETAM | Sourceable in Canada |
| SANIS HEALTH INC | 4 | 3 | LEVETIRACETAM | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 3 | 3 | ACH-LEVETIRACETAM | Sourceable in Canada |
| ANGITA PHARMA INC. | 3 | 3 | AG-LEVETIRACETAM | Sourceable in Canada |
| APOTEX INC | 3 | 3 | APO-LEVETIRACETAM | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-LEVETIRACETAM | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | PRO-LEVETIRACETAM - 250, PRO-LEVETIRACETAM - 500, PRO-LEVETIRACETAM - 750 | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 3 | 3 | LEVETIRACETAM | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (refers to Dosage Forms, Composition and Packaging section). |
| Storage | Not explicitly detailed in the provided text (refers to Storage and Stability section). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Levetiracetam |
|---|---|
| ATC code | N03AX14 |
| AHFS class | 28:12.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02414791 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2414791 |
| Brand name | ABBOTT-LEVETIRACETAM |
| Generic / active ingredient | LEVETIRACETAM : 500 MG |
| Market authorization holder | ABBOTT LABORATORIES, LIMITED |
| Health Canada schedule | Prescription |
| ATC code | N03AX14 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AX |
| Current status | CANCELLED POST MARKET |
| Status date | 31-Dec-2015 |
| Original market date | 2014-05-30 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: Adjunctive therapy. Recommended dose up to 3000 mg/day. Withdraw gradually to minimize potential of increased seizure frequency. Dosage adjustment required for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to levetiracetam, other ingredients in the formulation, or component of the container.
Warnings and precautions
Potential for somnolence/dizziness (caution driving). Risk of suicidal ideation/behavior. Serious skin reactions (SJS, TEN, DRESS). Gradual withdrawal required.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
47 of 109 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-LEVETIRACETAM | 750 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02399792 |
| ACH-LEVETIRACETAM | 500 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02399784 |
| ACH-LEVETIRACETAM | 250 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02399776 |
| AG-LEVETIRACETAM | 750 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02485214 |
| AG-LEVETIRACETAM | 250 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02485192 |
| AG-LEVETIRACETAM | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02485206 |
| APO-LEVETIRACETAM | 250 MG | TABLET | APOTEX INC | MARKETED | 02285924 |
| APO-LEVETIRACETAM | 750 MG | TABLET | APOTEX INC | MARKETED | 02285940 |
| APO-LEVETIRACETAM | 500 MG | TABLET | APOTEX INC | MARKETED | 02285932 |
| AURO-LEVETIRACETAM | 750 MG | TABLET | AURO PHARMA INC | MARKETED | 02375265 |
2 · Same class — other molecules in ATC N03AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levetiracetam | ABBOTT-LEVETIRACETAM · ACH-LEVETIRACETAM · AG-LEVETIRACETAM · APO-LEVETIRACETAM · +31 more | 109 | 47 | Yes |
| Topiramate | ABBOTT-TOPIRAMATE · ACCEL-TOPIRAMATE · ACH-TOPIRAMATE · AG-TOPIRAMATE · +32 more | 125 | 42 | Yes |
| Lacosamide | ACH-LACOSAMIDE · AG-LACOSAMIDE · ALEMBIC-LACOSAMIDE · APO-LACOSAMIDE · +12 more | 66 | 41 | Yes |
| Lamotrigine | AG-LAMOTRIGINE · APO-LAMOTRIGINE · AURO-LAMOTRIGINE · DOM-LAMOTRIGINE · +13 more | 48 | 29 | Yes |
| Brivaracetam | APO-BRIVARACETAM · AURO-BRIVARACETAM · BRIVLERA | 14 | 14 | Yes |
| Perampanel | FYCOMPA · TARO-PERAMPANEL | 13 | 12 | Yes |
| Cenobamate | XCOPRI | 11 | 8 | Yes |
| Stiripentol | DIACOMIT | 4 | 3 | Yes |
| Cannabidiol | EPIDIOLEX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AF | Carbamazepine · Eslicarbazepine · Oxcarbazepine · Rufinamide | 86 | 33 |
| N03AG | Valproic Acid · Vigabatrin | 75 | 19 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AB | Fosphenytoin · Phenytoin · Phenytoin, Combinations | 17 | 8 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ABBOTT-LEVETIRACETAM called?
The same molecule, Levetiracetam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| LEVETIRACETAM | Latin | Brazil |
| Keppra | Latin | Australia, Bahrain, Brazil, Czechia, Morocco, Norway, Saudi Arabia |
| VEEPI | Latin | Brazil |
| APO-Levetiracetam | Latin | Australia |
| Levetiracetam Accord | Latin | Czechia, Norway |
| Levetiracetam GH | Latin | Australia |
| Antagra | Latin | Bahrain, Saudi Arabia |
| ILUDRAL | Latin | Brazil |
| Levactam | Latin | Australia |
| Levetiracetam SZ | Latin | Australia |
| Levetiracetam Viatris | Latin | Australia |
| LEVETIRACETAM-WGR | Latin | Australia |
| ANTARA | Latin | Brazil |
| DRETACEN | Latin | Czechia |
| EPILETAM | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.